ABSTRACT

Introduction

Breast cancer is the most common cancer in women worldwide. Despite the development of targeted therapies that have significantly improved survival, effective breast cancer evaluation is still challenging due to the complexity of this disease. Liquid biopsy might allow the noninvasive real-time monitoring of the tumor course and response to therapy.

Areas covered

This review summarizes the latest advances on the various circulating analytes used as liquid biopsy (circulating tumor cells and tumor DNA, and more recently extracellular vesicles) for breast cancer work-up. Several studies have shown that in breast cancer, liquid biopsy can be used to predict disease progression or relapse and to monitor the treatment response. Moreover, circulating analytes are more easily accessible than tissue biopsies and might represent a powerful source of specific knowledge.

Expert opinion

The new evidence coming from the increasing number of clinical trials, and the continuous improvements in the technologies to isolate these tumor-derived analytes should strengthen the role of liquid biopsy in the clinic for personalized medicine of breast cancer.

中文翻译：

---

乳腺癌液体活检的临床相关性：2020 年更新。

摘要

介绍

乳腺癌是全球女性中最常见的癌症。尽管开发了显着提高生存率的靶向疗法，但由于这种疾病的复杂性，有效的乳腺癌评估仍然具有挑战性。液体活检可能允许对肿瘤病程和对治疗的反应进行无创实时监测。

覆盖区域

本综述总结了用作乳腺癌检查液体活检（循环肿瘤细胞和肿瘤 DNA，以及最近的细胞外囊泡）的各种循环分析物的最新进展。多项研究表明，在乳腺癌中，液体活检可用于预测疾病进展或复发并监测治疗反应。此外，循环分析物比组织活检更容易获得，并且可能代表特定知识的强大来源。

专家意见

来自越来越多的临床试验的新证据，以及分离这些肿瘤衍生分析物的技术的不断改进，应该会加强液体活检在乳腺癌个性化医疗临床中的作用。